Restoration of spermatogenesis in azoospermic mice by bone marrow mesenchymal stromal/stem cells conditioned medium

Rano Zhankina  
Astan University of Medical Sciences

Alireza Afshar  
Bushehr University of Medical Sciences

Zohreh Farrar  
Bushehr University of Medical Sciences

Arezoo Khorademehr  
Bushehr University of Medical Sciences

Mandana Baghban  
Shiraz University of Medical Sciences

Mahmud Suleiman  
Astan University of Medical Sciences

Mohammad Reza Dorvash  
Shiraz University of Medical Sciences

Neda Baghban  
Bushehr University of Medical Sciences

Farhad Rahmanifar  
Shiraz University

Nader Tanideh  
Shiraz University of Medical Sciences

Omid Koohi Hosseinabadi  
Shiraz University of Medical Sciences

Ali Arabi Monfared  
Shiraz University of Medical Sciences

Shahrokh Zare  
Shiraz University of Medical Sciences

Zahra Khodabaner  
Shiraz University of Medical Sciences

Mojtaba Farjam  
Fasa University of Medical Science

Iraj Nabipour
Research Article

Keywords: Azoospermia, Mesenchymal stromal/stem cell, Conditioned media, Bone marrow, Adipose tissue

DOI: https://doi.org/10.21203/rs.3.rs-169243/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

One of the main cause of male infertility is non-obstructive azoospermia, which is not manageable medically. The first aim of the current research was to show the effect of extracellular vesicle-contained conditioned media (CM) instead of mesenchymal stromal/stem cells (MSCs) for treatment of non-obstructive azoospermia. In the next step, we aimed to study the differentiation potential of MSCs into spermatocytes after injection of MSCs in mice seminiferous tubules. This study has provided an applied treatment for busulfan-induced azoospermia using adipose tissue-derived (AT-MSCs) and bone marrow-derived MSCs (BM-MSCs) and bone marrow CM (BMCM) in animal models. In this regard, 30 male adult Balb/C mice (30±5g) and two female eGFP/+ Balb/C mice (30±5g) were used to design experimental groups and to culture stem cells, respectively. Then, six groups including intact control, azoospermia, AT-MSC therapy, BM-MSC therapy, BMCM therapy, and spontaneous healing groups were considered. All groups except intact control were induced azoospermia by injecting two doses of busulfan (10 mg/kg) with 21 days’ interval. Testes of all mice were removed and studied through histomorphometry and flow cytometry analysis 60 days after treatment. Histomorphometry and flow cytometry evaluation of testes showed normal morphology of most of the seminiferous tubules of therapy groups as well as successful recovery of spermatogenesis, but spermatogenesis was not observed in the azoospermia group. It is worth notable that the results of the BM-MSC therapy group were more favorable than other therapy groups. Consequently, AT-MSC, BM-MSC and BMCM can be strongly suggested as candidates in the therapy of azoospermia.

Introduction

Infertility is one of the highest serious global severe disabilities that influenced the quality of life of many couples world wild. In humans, male infertility accounts for 8–12% of reproductive-aged couples (Duca et al., 2019), which can be caused by congenital or acquired urogenital abnormalities, malignancies, urogenital tract infections, increased scrotal temperature (e.g. as a consequence of varicocele), endocrine disturbances, genetic abnormalities, immunological factors, and etc. (Punab et al., 2017). Azoospermia with two types of obstructive or non-obstructive azoospermia affects about 1.3% of all men (Punab et al., 2017). This static refers to a notable population in the field of male infertility and shows the importance of efforts, which are being made today to treat non-obstructive azoospermia (Zhang et al., 2014).

Although different therapies (for example hormone therapy and testicular sperm extraction) are recommended depending on the type and cause of azoospermia (Shin et al., 2016; Tharakan et al., 2020), about 67% of azoospermia is related to untreatable testicular disorders, which result in spermatogenic failure (Esteves, 2015). Accordingly, researchers have recently tried to develop stem cell transplantation-based therapies for azoospermia (Vij et al., 2018). These attempts arise from the view that on the one hand, spermatogenic epithelium contains germ cells (spermatogonia) with the ability to repair damages on their own, and on the other hand, if stem cells are placed in testis with defected spermatogonia, they will restore the function of these spermatogonia and induce differentiation/proliferation of them or differentiate to spermatogonia (Vij et al., 2018).
Various sources of stem cells are used, including embryonic stem cells or pluripotent stem cells, but the use of mesenchymal stromal/stem cells (MSCs) is of great interest as they are free from ethical problems of embryonic stem cells and can be obtained from various sources such as bone marrow, adipose tissue, dental pulp, and menstrual blood, all of which have a high ability to differentiate into different tissues (Shirazi et al., 2017). Moreover, MSCs have been shown to secrete cytokines and growth factors that have anti-inflammatory, immune-modulating, anti-apoptotic, and proliferative effects which all are packed in extracellular vesicles (EVs) (Galipeau and Sensébé, 2018). Conditioned media (CM) of stem cell culture contains the EVs which are secreted from the cells (Park et al., 2019). CM can induce tissue regeneration (Almeria et al., 2019; Bazoobandi et al., 2020) or cell differentiation (Jahromi et al., 2017; Shah et al., 2016). In vitro effects of CM on germ cell regeneration has been shown (Shah et al., 2016). However, to the best of our knowledge CM has not been used for the treatment of azoospermia, yet.

On the other hand, bone marrow-derived MSCs (BM-MSCs) and adipose tissue-derived MSCs (AT-MSCs) have recently been considered by many researchers. BM-MSCs and AT-MSCs are used to produce male germ cells in vitro (Ghasemzadeh-Hasankolaei et al., 2016; Luo et al., 2019) and in vivo (Karimaghai et al., 2018; Tamadon et al., 2015). Less invasive, less costly, powerful immunomodulatory effects, more proliferative potential, and more secretion of growth factors and cytokines are the most important priorities of AT-MSCs compared to BM-MSCs for cell therapy (Xu et al., 2017). As far as we know, there is no comparison between these two sources for cell therapy of azoospermia.

Despite the effectiveness of MSC therapy in the treatment of azoospermia (Zhanbyrbekuly et al., 2020), it has yet remained unknown whether transplanted stem cells differentiate to spermatocytes. Based on the existing data, this study is the first attempt to compare the effect of allotransplanting of AT-MSC and BM-MSC and BMCM in seminiferous tubules of busulfan induced azoospermia in Balb/C mice. Therefore, the first goal of the present study was to show the effect of EV-contained CM in comparison with MSCs for the treatment of non-obstructive azoospermia. The next aim of this study was to show the differentiation potential of inter-tubular injected MSCs to spermatocytes in mice seminiferous tubules.

**Materials And Methods**

**2.1. Animals and ethics**

Thirty male adult Balb/C mice (30±5 g) were provided from Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, and two female eGFP+/+Balb/C mice were gifted from Royan Institute and were housed in the laboratory under the controlled condition of a temperature of 22±2°C, the humidity of 55±5% and lightening cycle of 12 h light/dark. They were fed ad libitum standard diet. All the manipulations were performed in accordance with the regulations of working with laboratory animals and approved by the Ethical Committee of Astana Medical University, Astana, Kazakhstan (Protocol No. 10).
2.2. Isolation and culture of BM-MSC and AT-MSC

BM-MSCs were isolated from femurs of two eGFP+/+ Balb/C mice by modification of the previously reported method (Tamadon et al., 2015). In sterile condition and after soaking the separated thigh of mice in 70% ethanol, the skin has been removed. After cutting the two ends of the thigh bone, the thigh with the muscles was put in a blue-color sampler tip which its upper half parts had been cut. The tips were placed in 1.5 mL micro-tubes. Then all micro-tubes were centrifuged at 1500 xg for 15 min at 37°C. The collected BM at the end of micro-tubes were mixed with 1 mL of the Dulbecco's modified eagle medium (DMEM) without fetal bovine serum (FBS, Gibco, U.S.A.) and penicillin-streptomycin antibiotics (Gibco, U.S.A.). Then, the BM suspension was transferred to a 25 cm² flask containing DMEM medium along with 10% FBS and 1% penicillin-streptomycin. The flask was incubated at 37°C, standard humidity, and 5% CO₂ concentration. The culture medium was changed 24 h after the beginning of incubation, then every 72 h under sterile conditions, to remove unattached cells and debris. After increasing the density of the cells adhering to the flask to 80%, the cells were passaged using trypsin enzyme. For this purpose, the trypsin enzyme was added to the flask for 3 min to separate the cells sticking to the flask floor. Then, 2 mL of 10% FBS culture medium was poured in to the flask for neutralizing the trypsin enzyme effect. Collecting cells separated from the medium in the first passage was performed and continued till the third passage.

AT-MSCs were provided using ovarian AT of the same mice used in the previous step. Briefly, AT was minced into tiny parts. The AT parts were explanted in a T75 flask. After 15 min of pasting the explants by drying the attachment surface of the explant and flask, they were gently covered with a drop of FBS. The explanted AT were incubated for 48 h in an incubator containing 5% CO₂ at 37°C and saturated humidity. Then DMEM with 10% FBS and 1% penicillin and 1% streptomycin were gently added. By daily monitoring of the border of attachment surface of AT explants and flask, 5 days after explanting and observation of AT-MSCs, the explants were removed by tapping the bottom of flask and media replacement. Then, DMEM containing 10% FBS, 2 mM of L-glutamine (Invitrogen, Netherlands), 1% penicillin and 1% streptomycin were added and kept in a CO₂ incubator. The sub-culturing of cells was continued till the third passage.

2.3. Flow cytometry characterization of MSCs

To confirm the isolation of BM-MSCs and AT-MSCs and the non-appearance of hematopoietic stem cells, flow cytometry analysis was used. In this regard, the non-appearance of hematopoietic stem cell-specific surface marker expression (CD34 and CD45) and the existence of specific surface area marker expression on BM-MSCs and AT-MSCs (CD44 and CD105) in the isolated cells based on the method previously described were considered (Ghaneialvar et al., 2018). Briefly, 5×10⁵ cells of the third passage were incubated with specific individual monoclonal antibodies, conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) in 250 mL phosphate-buffered saline (PBS) for half an hour at ambient temperature in the dark. CD34, CD45, CD44, and CD105 primary antibodies were used and
cells were diluted using 4 mL PBS. The diluted cells were centrifuged, and re-suspended in 600 mL solution containing PBS–formaldehyde 2%. Then, they were studied using a four-color FACS Calibur flow cytometer (BD bioscience), and obtained data were analyzed by FlowJo software (FlowJo LLC, Ashland, OR, USA). Immunoglobulin G (IgG)1 FITC and IgG1 PE monoclonal antibodies were applied as isotype controls.

2.4. Osteogenic, chondrogenic, and adipogenic characterization of MSCs

In order to determine the potential of osteogenic, chondrogenic, and adipogenic differentiation of AT-MSC and BM-MSC, the cells of third passage were used. MSCs were in 6-well plates. After fusion, 70% of the cells were grown in an osteogenic, chondrogenic, or adipogenic environment for 3 weeks. For osteogenic differentiation, the hV-MSCs at 90% confluence were exposed to an osteogenic differentiation kit (Stem Cell Technology, Iran). Changing the medium was performed two times per week for 3 weeks. After 21 days, osteogenic differentiation was confirmed by Alizarin red staining (Stem Cell Technology, Iran). For chondrogenic induction, hV-MSCs at the confluence of 90% were exposed to a chondrogenic differentiation kit (Stem Cell Technology, Iran). Induction continued 3 weeks and chondrogenic induction was confirmed by Alcian blue staining (Stem Cell Technology, Iran). For adipogenic induction, hV-MSCs at the confluence of 90% were exposed to adipogenic differentiation kit (Stem Cell Technology, Iran). Induction continued 3 weeks and induction of adipogenic was confirmed by Oil Red O staining (Stem Cell Technology, Iran). MSCs without differentiation media were stained simultaneously with three protocols as control.

2.5. Preparation of BMCM

In order to obtain the BMCM, BM-MSCs at the third passage were cultured at a density of $10^6$ cells in a T75 flask. The BM-MSCs at 80% confluence were rinsed three times with PBS and 10 mL of FBS-free DMEM media were replaced. Collection of the media was performed following 48 h incubation and they were filtrated using a 0.2-μm filter to eliminate cellular debris. The BMCM were stored at -80°C until injection or isolation and confirmation of EVs. EVs were evaluated by scanning electron microscopy (SEM) or transmission electron microscopy (TEM).

2.6. Isolation of EVs of BMCM by kit

The CM was collected and centrifuged in 2000 ×g and 4°C for 30 min. The supernatant was harvested and then added to precipitant reagent of Exovista kit (PerciaVista Co., Iran) with 1:1 ratio. The mixture was kept at 4°C for 14 h. To continue, the mixture was centrifuged in 10000 ×g and 4°C for 1 h. The EVs’ pellet was observed at the bottom of the falcon and collected for further analysis.
2.7. SEM imaging of EVs of BMCM

SEM imaging was performed to show EVs in the isolated BMCM (Reclusa et al., 2020). The isolated EVs were fixed with 2.5% formalin buffer solution in PBS for 10 min. Attaching and drying EVs on stubs were performed following the fixation step. Deposition of a 15 nm conductive gold layer was performed using sputter coating for inhibition of charging and for improving the secondary electron signal. The SEM images of EVs were obtained by the FEI Quanta 250 FEG environmental SEM. The microscope was operated at 30 kV.

2.8. TEM imaging of EVs of BMCM

TEM imaging was performed to confirm the presence of EVs in BMCM (Cizmar and Yuana, 2017). Firstly, a 20 μL drop of the sample was located on a formvar Carbon film coated on 300 mesh copper grid (EMS) for 2 min. A filter paper was used to adsorb excess liquid and then, the sample was negatively stained with a 20 μL drop of 2% uranyl acetate for 1-2 min. One more time, a filter paper was used to adsorb excess liquid and the grid was allowed to air dry. Grids were examined either on a Zeiss EM10C transmission electron microscope (Zeiss Co., Germany) operating at an acceleration voltage of 100 kV.

2.9. Induction of azoospermia

In order to model the experimental groups, the male adult Balb/C mice were randomly divided into six equal groups (Figure 1A).

- An intact control group (n = 6): the mice did not receive busulfan and treatment.
- Azoospermia group (n = 6): the left testicles of mice received busulfan injections without treatment and were sampled 60 days following the last busulfan injection.
- BMCM therapy group (n = 6): the right testicles of mice received busulfan injections and then treated with BMCM and were sampled 60 days following the last busulfan injection.
- BM-MSC therapy group (n = 6): the right testicles of mice received busulfan injections and then treated with BM-MSC and were sampled 60 days following the last busulfan injection.
- AT-MSC therapy group (n = 6): the right testicles of mice received busulfan injections and then treated with AT-MSC and were sampled 60 days following the last busulfan injection.
- Spontaneous healing group (n = 6): the mice received busulfan injections and were left without any treatment and were sampled 120 days following the last busulfan injection.

Then, azoospermia was induced in mice of all groups except those of the intact control group. To induce azoospermia in mice, busulfan was used according to previous reports (Tamadon et al., 2015). Briefly, the azoospermia groups were received two doses of busulfan (10 mg/kg, Busilvex®; Pierre Fabre Medicament Boulogne, France) with 21 days’ interval. Thirty-five days following the second injection, their
testes were removed and fixed in 10% formalin buffer solution for histomorphometry studies. The epididymis was collected from all groups and after incubating in phosphate buffer saline (PBS), spermatozoa were evaluated by flow cytometry. The testes of control group mice, which were not received busulfan, were assessed through similar procedures.

2.10. BM-MSCs and AT-MSCs transplantation

Preparing an injecting set for a fine cell injection has been previously described (Kasraeian et al., 2020). The mice in cell and CM therapies’ groups (n=18, AT-MSC therapy, BM-MSC therapy, and BMCM therapy groups) were surgically allotransplanted (Rahmanifar et al., 2016). Cell suspensions or CM were mixed with vital stain, sterile trypan blue. The mice were anesthetized with xylazine and ketamine (Alfasan, Netherland) 35 days following the second injection of busulfan. After preparation of abdominal area in dorsal recumbence position, a 1 cm midline abdominal incision was made to reach the peritoneum and testicle. The fat pad and then right testicle were carefully pulled out using iris forceps under a stereomicroscope (Model SZN, Optika, Italy). Simultaneously, a thin sterile plastic black card with a 30° V-neck as a holder was placed under the testicle. A polyethylene tube attached to a one-milliliter syringe, was filled with the cell suspension (10⁶ cells in 100 μL). The tip of the pipette was carefully inserted into the efferent duct, and slowly threaded a few millimeters toward the testes (Figure 1B). The blue suspension was injected as slowly as possible to avoid moving the pipette and the entrance of the blue suspension into the seminiferous tubules was observed (Figure 1C). Finally, the testes were returned back into the abdomen and the abdominal wall was closed. The untreated testicles on the left side were considered as azoospermia groups.

2.11. Histological and histomorphometric assessments

Sixty days after treatment, the animals’ testes were removed after euthanizing with ether. Next, they were put in paraffin for histological and histomorphometric assessments after fixing in 10% formalin buffer solution and dehydrating using alcohol. For each testis, five horizontal cross-sections with a thickness of 5 μm were made from appropriate regions and stained with hematoxylin-eosin for histological assessment. Then, they were studied carefully by means of a light microscope (Model CX21, Olympus, Tokyo, Japan) to evaluate the presence of spermatogonia, spermatocytes, and spermatids in all tubules. Five circular cross-sections were provided from different areas of the tubules and the inner, outer, and total diameters of all the tubules were determined using the Dinocapture software (version 2.0, Dino-Eye, San-Chung, Taiwan). Using the mean of two diameters (D1, D2) at right angles, the average diameter of the seminiferous tubules (D) was specified. Using diameter data, cellular (germinal epithelium), luminal, and cross-sectional areas were determined. In the seminiferous tubules, the cross-sectional area (A) was obtained by the equation A= πD²/4, where D is the average diameter of the tubules, and π is 3.142. The number of seminiferous tubule profiles per unit area was also considered. The area of cells was
computed through subtraction of the luminal area from the cross-sectional area. In the seminiferous tubules, determination of the numerical density ($N_v$) was performed using the following equation:

$$N_v = \frac{N_A}{D + T}$$

where $N_A$ indicates the number of profiles per unit area, $D$ displays the average diameter of the seminiferous tubules, $T$ shows the average section thickness, and indicates the number of tubules per unit volume.

The spermatogenesis index including the presence of spermatogenic cells throughout the testicular tissue, affecting the number of cell layers, cell types, and the existence of spermatids in the tubules was studied and the spermatogenic potential of testes was rated based on the modified scale of 0 to 7 (Rahmanifar et al., 2016) as following: 0, no spermatogonia; 1, the existence of only spermatogonia; 2, the presence of spermatocytes; 3, the presence of spermatids up to 25 in each tubule; 4, the presence of 25-50 spermatids per tubule; 5, the appearance of 50-75 spermatids per tubule; 6, the appearance of 75-100 spermatids per tubule; and 7, more than 100 spermatids per tubule.

2.12. Flow cytometry of enhanced green fluorescent protein expression (eGFP)

Flow cytometry was conducted to prove the presence of eGFP spermatozoa. For this goal, epididymis was collected from all groups and was incubated in 1 mL PBS at 37°C for 15 min. Then, they were resuspended in a total volume of 1.8 mL, after adding 800 μL of 10% formalin buffer solution, and then stored on ice until analysis with a flow cytometry under illumination in the range of the 360–400 nm that is related to eGFP fluorescence (Balestrini et al., 2020). A four-color FACS Calibur flow cytometer (BD bioscience) was used to collect the data and data were analyzed using the CellQuest Pro software package (BD bioscience).

2.13. Imaging of eGFP spermatozoa

The imaging of eGFP spermatozoa from the epididymis of treated mice was conducted using an epifluorescent microscope (XDS 3FL4, Optika, Italy) to prove the green fluorescent nature of spermatozoa produced in cell therapy groups. For this purpose, a red filter (594 nm) and a green filter (498 nm) were used.

2.14. Statistical analysis

Kolmogorov-Smirnov test was conducted to study the normal distribution of data of histomorphometry indices of seminiferous tubules. All data were presented as means and standard error (mean ± SE) and analyzed using one-way ANOVA and Tukey post-hoc test (SPSS for Windows, version 20, SPSS Inc,
Chicago, Illinois, USA). The Mann-Whitney U test was used to assess the spermatogenesis index. A P-value of less than 0.05 was considered statistically significant.

**Results**

3.1. **Isolated BM-MSCs and AT-MSCs show stem cells characteristics**

Adherence to plastic and the existence of a homogeneous fibroblast-like population were observed for cultured BM-MSCs and AT-MSCs. Additionally, studying the adipogenic, osteogenic, and chondrogenic differentiation abilities of BM-MSCs and AT-MSCs showed the successful differentiation of these cells to adipocytes with intracellular lipid droplets, chondrocytes, and osteoblasts, respectively. The diagrams obtained using FlowJo software for characterizing MSCs cell surface markers showed the presence of CD44 and CD105 and the absence of CD34 and CD45 in BM-MSCs and AT-MSCs.

3.2. **Isolated CM from BM-MSCs contained EVs**

In order to evaluate the quality of CM before injection, EVs visualization with SEM and TEM was performed. We isolated EVs with a commercial kit protocol that allows collecting EVs with a homogeneous diameter size. Furthermore, this protocol removed crystals, protein aggregates, and other residues obtained from CM. SEM images showed the EVs with 70–190 ± 10 nm diameter using this protocol. TEM images showed electron-lucent EVs with clear lipid bilayer with a diameter size of less than 200 nm.

3.3. **Histologic findings showed therapeutic effects of BMCM, BM-MSCs, and AT-MSCs**

Normal intact mice had condensed germinal epithelium in their seminiferous tubules, and all of the epididymis tubes were filled by spermatozoa (Figure 2A). However, the testes seminiferous tubules of the azoospermia group were empty and their spermatogenesis procedure was completely disrupted (Figure 2B). Seminiferous tubules revealed degenerative variations including germinal epithelia degenerations and seminiferous tubular atrophy in all tubules and no spermatozoa was found in their epididymis. Moreover, thickening of the walls of some epididymal tubes was observed in this group. On the other hand, in the BM-MSCs, AT-MSCs, BMCM, and even the spontaneous healing groups, Sertoli cells, formation of cells of lower layers of germinal epithelium spermatozoa and spermatogonia were observed in some seminiferous tubules (Figures 2C to 2F, respectively). Most of the tubules of these groups were nearly filled up with germinal cells including spermatogonia, primary spermatocytes, spermatids, and sperms. Most of the epididymis tubes of this group had spermatozoa, but less than the normal group
(data not shown). It is evident that between the MSCs therapy groups, the results relating to BM-MSCs therapy were closer to normal intact mice compared to the AT-MSCs therapy group.

3.4. Histomorphometry findings indicated the therapeutic effects of BMCM, BM-MSCs and AT-MSCs

Quantitative histomorphometry as well as qualitative histological analysis must be performed besides the qualitative histological analysis, which can be affected by operator-related bias and does not provide statistically assessable numerical data. Figure 3 indicates the histomorphometric indices of the seminiferous tubules in all studied groups. The cellular area chart shows that intact control, BMCM therapy, AT-MSC therapy, and spontaneous healing group had no significant difference (Figure 3A). Moreover, the maximum and minimum values of this index were related to BM-MSCs therapy and azoospermia groups, respectively. The cross-sectional area chart shows that the maximum and minimum total area of seminiferous tubules were related to the BM-MSC therapy and azoospermia groups (Figure 3B). Control, BMCM therapy, and spontaneous healing groups showed a statistically similar total area. This index had lower values in the AT-MSC therapy group than the control group. The graph related to the number of tubules indicates the maximum amount of this index for the azoospermia group (Figure 3C). This index was statistically the same in other groups except for the spontaneous healing group, which showed a slightly higher number of tubule than other groups. The spermatogenesis index of seminiferous tubules of the azoospermia group was minimum (Figure 3D). The control and BMCM therapy groups had no significant difference in terms of this index. AT-MSC therapy, BM-MSC therapy, and spontaneous healing groups showed a slightly higher value of this index compared to the control group.

3.5. Flow cytometry of eGFP sperms confirmed in vivo differentiation of BM-MSCs and AT-MSCs to spermatozoa

The results of flow cytometry have been shown in Figure 4. According to this figure, 4.07%, 61.0%, 61.5%, 20.9%, 67.4% and 1.60% eGFP spermatozoa found in intact control, GFP control, mixed of intact and the eGFP controls, the AT-MSC therapy, the BM-MSC therapy, and the spontaneously healed azoospermia groups, respectively (Figure 4A). The fluorescent-protein-based imaging of spermatozoa produced in cell therapy groups imaging proved the green fluorescent nature of spermatozoa of MSCs therapy groups (Figures 4B to 4E). Spermatozoa were clearly observed in the image obtained by using a green filter (498 nm), while the image taken using a red filter (594 nm) were not clear. In the flow cytometry analysis, it was expected to observe 0% eGFP subset in the control group, while this value was 4.07% that can be considered as noise. In contrast, in the eGFP control group, it was expected to observe 100% GFP subset, but this value was 61.0%. This difference can be assigned to those sperms whose direction was not appropriate.

Discussion
The CM and MSC therapies as promising therapy for non-obstructive azoospermia were investigated in mice. Our study for the first time indicated the effects of BMCM for the healing of chemotherapy disrupted the germinal layer in mice. Consistent with our findings, applications of Sertoli cell–CM on the azoospermia model induced spermatogenesis in mice (Panahi et al., 2020). In addition, 10% of the CM from canine amniotic membrane-derived MSCs enhanced the quality of frozen–thawed sperm cells (Mahiddine et al., 2020). Since EVs of MSCs contains cell paracrine factors (Yuan et al., 2020), the application of BMCM for azoospermia clinical studies seems to be promising. MSCs-derived CM contains anti-apoptotic factors and growth factors, and it has been investigated in cell-free therapies to simulate the paracrine effects of stem cells on the ovary after chemotherapy (Hong et al., 2020). Several different cytokines and growth factors with therapeutic properties are secreting from stem cells into their CM, which may play key roles in the regeneration and angiogenesis of damaged tissues (Gama et al., 2018). Epidermal growth factor (EGF), fibroblast growth factor 2/basic fibroblast growth factor (FGF-2/bFGF), hepatocyte growth factor (HGF), insulin-like growth factor I (IGF-I), insulin-like growth factor II (IGF-II), platelet-derived growth factor (PDGF) and vascular endothelial-derived growth factor (VEGF) are the important growth factors in the CM of MSCs (Noverina et al., 2019). Furthermore, the presence of antioxidants in the CM (Mahiddine et al., 2020), in combination with cytokines and growth factors may have an effect on spermatogenesis of azoospermia mice.

Moreover, the findings of our study showed the potential of BM-MSCs and AT-MSCs differentiation to spermatozoa. The flow cytometry graphs related to AT-MSCs therapy and BM-MSCs therapy showed the presence of eGFP sperms indicating the differentiation of transplanted MSCs to sperm. However, the higher percentage of eGFP subset in BM-MSCs therapy group (67.4%) than AT-MSCs therapy group (20.9%) revolves higher potential of BM-MSCs to differentiate to sperm compared to AT-MSCs. Additionally, by comparing the graph of the BM-MSCs therapy group with the eGFP control group, it can be concluded that nearly all sperms in the BM-MSCs therapy are GFP+ that also confirms a higher ability of BM-MSCs to differentiate to spermatozoa than AT-MSCs. Germ cell line formation from pluripotent teratocarcinoma cells and successful in vitro generation of offspring mice from embryonic stem cell-derived germ cells has been reported for the first time (Nayernia et al., 2004; Nayernia et al., 2006b). The successful differentiation of mice BM-MSCs into male germ cells in vitro was also reported (Nayernia et al., 2006a). The trans-differentiation of BM-MSCs into germ cells, Leydig cells, and Sertoli cells, was shown in busulfan-treated infertile mice (Drusenheimer et al., 2007; Lue et al., 2007). Human fetal lung- and umbilical cord-derived MSCs were also shown to transdifferentiate into sperm-like cells (Hua et al., 2011; Kim et al., 2008). Coherently, recovery of fertility in azoospermia rats following injection of AT-MSCs and their trans-differentiation to spermatozoa have been shown (Cakici et al., 2013). Moreover, the number of tubules except for the azoospermia group with remarkable number of tubules than control and other groups was comparable to the control. The total area and cellular area of all groups except azoospermia, which was remarkably lower than the control group, were comparable with the control group, confirming the successfulness of studied therapy in treating azoospermia mice. Moreover, it is notable that higher values of these indexes for the BM-MSCs therapy group in comparison to others demonstrate more significant effectiveness of this therapy method over other studies in the current work.
However, induction of spermatogenesis with AT-MSCs and BM-MSCs has been shown in various animal models (Cakici et al., 2013; Hajihoseini et al., 2018; Hajihoseini et al., 2017; Karimaghai et al., 2018; Mehrabani et al., 2015; Rahmanifar et al., 2016; Tamadon et al., 2015), although these two sources were compared by our findings for the first time and the priority of BM-MSCs for this purpose was shown.

**Conclusions**

Spermatogenesis was effectively induced in seminiferous tubules of busulfan-induced azoospermic mice through allotransplantation of BMCM, AT-MSCs, and BM-MSCs. BMCM and its related EVs could induce recovery of the germinal layer in a model of non-obstructive azoospermia. However, the attained results using the BM-MSCs therapy was slightly more effective than AT-MSCs and BMCM therapies. The results of histomorphometric and flow cytometry analysis have been clearly demonstrated that the recovery of spermatogenesis using MSCs occurs through two parallel mechanisms. First, repairing defected spermatogonia and second, differentiation to spermatogonia as a result of the effect of their CM. These golden achievements provide a platform for the clinical study of CM therapy of azoospermia in men.

**Declarations**

**Ethics approval and consent to participate**

All the manipulations were performed in accordance with the regulations of working with laboratory animals and approved by the Ethical Committee of Astana Medical University, Astana, Kazakhstan (Protocol No. 10).

**Consent for publication**

Not applicable.

**Availability of data and material**

Data are available as requested.

**Funding**

This study was partly funded by a grant from the Department of Urology and Andrology, Astana Medical University, Astana, Kazakhstan by Dr. Ulanbek Zhanbyrbekuly (Grant no. AP08857153) and Fasa University of Medical Science by Dr. Mojtaba Farjam. Some part of this study has been financially supported by The Council for Stem Cell Sciences and Technologies, affiliated to the Iranian Vice Presidency for Science and Technology for the development of exosome isolation kit.
Competing interests

The authors announced that there are no conflicts of interest.

Authors' contributions

A.T., U.Z., R.S., M.F. and I.N. conceived and designed the format of the manuscript. R.Z., A.A., Z.F., A.K., M.B., M.S., M.R.D., N.B., F.R., N.T., O.K.H., A.A.M., S.Z. and Z.K. collected data, analysed the findings, drafted and edited the manuscript. A.T., U.Z., R.S., M.F. and I.N. reviewed the manuscript. All authors contributed to the critical reading and discussion of the manuscript. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

The authors would like to thank the Stem Cells Technology Research Center for their collaboration with laboratories. The authors wish to thank Dr. Yaser Tahamtani from Royan Institute for his kindly supports.

References

Almeria, C., Weiss, R., Roy, M., Tripisciano, C., Kasper, C., Weber, V., Egger, D., 2019. Hypoxia conditioned mesenchymal stem cell-derived extracellular vesicles induce increased vascular tube formation in vitro. Frontiers in bioengineering and biotechnology 7, 292.

Balestrini, P.A., Jabloñski, M., Schiavi-Ehrenhaus, L.J., Marín-Briggiler, C.I., Sánchez-Cárdenas, C., Darszon, A., Krapf, D., Buffone, M.G., 2020. Seeing is believing: Current methods to observe sperm acrosomal exocytosis in real time. Molecular Reproduction and Development.

Bazoobandi, S., Tanideh, N., Rahmanifar, F., Zare, S., Koohi-Hosseinabadi, O., Razeghian-Jahromi, I., Dianatpour, M., Ahmadi, M., Khoradmehr, A., Nabipour, I., 2020. Preventive Effects of Intrauterine Injection of Bone Marrow-Derived Mesenchymal Stromal Cell-Conditioned Media on Uterine Fibrosis Immediately after Endometrial Curettage in Rabbit. Stem Cells Int. 2020.

Cakici, C., Buyrukcu, B., Duruksu, G., Haliloglu, A.H., Aksoy, A., Isık, A., Uludag, O., Ustun, H., Subasi, C., Karaoz, E., 2013. Recovery of fertility in azoospermia rats after injection of adipose-tissue-derived mesenchymal stem cells: the sperm generation. BioMed research international 2013.

Cizmar, P., Yuana, Y., 2017. Detection and characterization of extracellular vesicles by transmission and cryo-transmission electron microscopy, In: Extracellular Vesicles. Springer, pp. 221-232.

Drusenheimer, N., Wulf, G., Nolte, J., Lee, J.H., Dev, A., Dressel, R., Gromoll, J., Schmidtke, J., Engel, W., Nayernia, K., 2007. Putative human male germ cells from bone marrow stem cells. Soc. Reprod. Fertil.
Suppl. 63, 69.

Duca, Y., Calogero, A.E., Cannarella, R., Condorelli, R.A., La Vignera, S., 2019. Current and emerging medical therapeutic agents for idiopathic male infertility. Expert Opin. Pharmacother. 20, 55-67.

Esteves, S.C., 2015. Clinical management of infertile men with nonobstructive azoospermia. Asian journal of andrology 17, 459.

Galipeau, J., Sensébé, L., 2018. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell stem cell 22, 824-833.

Gama, K.B., Santos, D.S., Evangelista, A.F., Silva, D.N., de Alcântara, A.C., dos Santos, R.R., Soares, M.B.P, Villarreal, C.F., 2018. Conditioned medium of bone marrow-derived mesenchymal stromal cells as a therapeutic approach to neuropathic pain: a preclinical evaluation. Stem Cells Int. 2018.

Ghaneialvar, H., Soltani, L., Rahmani, H.R., Lotfi, A.S., Soleimani, M., 2018. Characterization and classification of mesenchymal stem cells in several species using surface markers for cell therapy purposes. Indian Journal of Clinical Biochemistry 33, 46-52.

Ghasemzadeh-Hasankolaei, M., Eslaminejad, M.B., Sedighi-Gilani, M., 2016. Derivation of male germ cells from ram bone marrow mesenchymal stem cells by three different methods and evaluation of their fate after transplantation into the testis. In Vitro Cellular & Developmental Biology-Animal 52, 49-61.

Hajihoseini, M., Mehrabani, D., Vahdati, A., Hosseini, S.E., Tamadon, A., Dianatpour, M., Rahamanifar, F., 2018. Spermatogenesis after Transplantation of Adipose Tissue-Derived Stem Cells in Azoospermic Guinea Pigs: A Histological and Histomorphometric Study. Galen Medical Journal 7, 1000.

Hajihoseini, M., Vahdati, A., Ebrahim Hosseini, S., Mehrabani, D., Tamadon, A., 2017. Induction of spermatogenesis after stem cell therapy of azoospermic guinea pigs. Vet Arh 87, 333-350.

Hong, L., Yan, L., Xin, Z., Hao, J., Liu, W., Wang, S., Liao, S., Wang, H., Yang, X., 2020. Protective effects of human umbilical cord mesenchymal stem cell-derived conditioned medium on ovarian damage. Journal of Molecular Cell Biology 12, 372-385.

Hua, J., Qiu, P., Zhu, H., Cao, H., Wang, F., Li, W., 2011. Multipotent mesenchymal stem cells (MSCs) from human umbilical cord: potential differentiation of germ cells. African Journal of Biochemistry Research 5, 113-123.

Jahromi, I.R., Mehrabani, D., Mohammadi, A., Seno, M.M.G., Dianatpour, M., Zare, S., Tamadon, A., 2017. Emergence of signs of neural cells after exposure of bone marrow-derived mesenchymal stem cells to fetal brain extract. Iranian journal of basic medical sciences 20, 301.

Karimaghaci, N., Tamadon, A., Rahamanifar, F., Mehrabani, D., Jahromi, A.R., Zare, S., Khodabandeh, Z., Jahromi, I.R., Koohi-Hoseinabadi, O., Dianatpour, M., 2018. Spermatogenesis after transplantation of
adipose tissue-derived mesenchymal stem cells in busulfan-induced azoospermic hamster. Iranian journal of basic medical sciences 21, 660.

Kasraeian, M., Ghasemi, E., Dianatpour, M., Tanideh, N., Razeghian, I.J., Khodabandeh, Z., Dorvash, M.R., Zare, S., Hosseinabadi, O.K., Tamadon, A., 2020. In utero xenotransplantation of mice bone marrow-derived stromal/stem cells into fetal rat liver: An experimental study. International Journal of Reproductive BioMedicine 18, 701.

Kim, J., Seandel, M., Falciatori, I., Wen, D., Rafii, S., 2008. CD34+ testicular stromal cells support long-term expansion of embryonic and adult stem and progenitor cells. Stem Cells 26, 2516-2522.

Lue, Y., Erkkila, K., Liu, P.Y., Ma, K., Wang, C., Hikim, A.S., Swerdloff, R.S., 2007. Fate of bone marrow stem cells transplanted into the testis: potential implication for men with testicular failure. The American journal of pathology 170, 899-908.

Luo, Y., Xie, L., Mohsin, A., Ahmed, W., Xu, C., Peng, Y., Hang, H., Zhuang, Y., Chu, J., Guo, M., 2019. Efficient generation of male germ-like cells derived during co-culturing of adipose-derived mesenchymal stem cells with Sertoli cells under retinoic acid and testosterone induction. Stem Cell. Res. Ther. 10, 1-18.

Mahiddine, F.Y., Kim, J.W., Qamar, A.Y., Ra, J.C., Kim, S.H., Jung, E.J., Kim, M.J., 2020. Conditioned Medium from Canine Amniotic Membrane-Derived Mesenchymal Stem Cells Improved Dog Sperm Post-Thaw Quality-Related Parameters. Animals 10, 1899.

Mehrabani, D., Hassanshahi, M.A., Tamadon, A., Zare, S., Keshavarz, S., Rahmanifar, F., Dianatpour, M., Khodabandeh, Z., Jahromi, I., Tanideh, N., 2015. Adipose tissue-derived mesenchymal stem cells repair germinal cells of seminiferous tubules of busulfan-induced azoospermic rats. J. Hum. Reprod. Sci. 8, 103.

Nayernia, K., Lee, J.H., Drusenheimer, N., Nolte, J., Wulf, G., Dressel, R., Gromoll, J., Engel, W., 2006a. Derivation of male germ cells from bone marrow stem cells. Lab. Invest. 86, 654-663.

Nayernia, K., Li, M., Jaroszynski, L., Khusainov, R., Wulf, G., Schwandt, I., Korabiowska, M., Michelmann, H.W., Meinhardt, A., Engel, W., 2004. Stem cell based therapeutical approach of male infertility by teratocarcinoma derived germ cells. Hum. Mol. Genet. 13, 1451-1460.

Nayernia, K., Nolte, J., Michelmann, H.W., Lee, J.H., Rathsack, K., Drusenheimer, N., Dev, A., Wulf, G., Ehrmann, I.E., Elliott, D.J., 2006b. In vitro-differentiated embryonic stem cells give rise to male gametes that can generate offspring mice. Dev. Cell 11, 125-132.

Noverina, R., Widowati, W., Ayuningtyas, W., Kurniawan, D., Afifah, E., Laksmiawati, D.R., Rinendyaputri, R., Rilianawati, R., Faried, A., Bachtiar, I., 2019. Growth factors profile in conditioned medium human adipose tissue-derived mesenchymal stem cells (CM-hATMSCs). Clinical Nutrition Experimental 24, 34-44.
Panahi, S., Karamian, A., Sajadi, E., Aliaghaei, A., Nazarian, H., Abdi, S., Danyali, S., Paktinat, S., Abdollahifar, M.-A., Farahani, R.M., 2020. Sertoli cell–conditioned medium restores spermatogenesis in azoospermic mouse testis. Cell and Tissue Research 379, 577-587.

Park, K.-S., Bandeira, E., Shelke, G.V., Lässer, C., Lötvall, J., 2019. Enhancement of therapeutic potential of mesenchymal stem cell–derived extracellular vesicles. Stem Cell. Res. Ther. 10, 288.

Punab, M., Poolamets, O., Paju, P., Vihlajiev, V., Pomm, K., Ladva, R., Korrovits, P., Laan, M., 2017. Causes of male infertility: a 9-year prospective monocentre study on 1737 patients with reduced total sperm counts. Hum. Reprod. 32, 18-31.

Rahmanifar, F., Tamadon, A., Mehrabani, D., Zare, S., Abasi, S., Keshavarz, S., Dianatpour, M., Khodabandeh, Z., Ghian Jahromi, I.R., Koohi-Hoseinabadi, O., 2016. Histomorphometric evaluation of treatment of rat azoospermic seminiferous tubules by allotransplantation of bone marrow-derived mesenchymal stem cells. Iranian Journal of Basic Medical Sciences 19, 653.

Reclusa, P., Verstraelen, P., Taverna, S., Gunasekaran, M., Pucci, M., Pintelon, I., Claes, N., de Miguel-Pérez, D., Alessandro, R., Bals, S., 2020. Improving extracellular vesicles visualization: From static to motion. Sci. Rep. 10, 1-9.

Shah, S.M., Saini, N., Singh, M.K., Manik, R., Singla, S.K., Palta, P., Chauhan, M.S., 2016. Testicular cell–conditioned medium supports embryonic stem cell differentiation toward germ lineage and to spermatocyte-and oocyte-like cells. Theriogenology 86, 715-729.

Shin, T., Kobayashi, T., Shimomura, Y., Iwahata, T., Suzuki, K., Tanaka, T., Fukushima, M., Kurihara, M., Miyata, A., Kobori, Y., 2016. Microdissection testicular sperm extraction in Japanese patients with persistent azoospermia after chemotherapy. Int. J. Clin. Oncol. 21, 1167-1171.

Shirazi, R., Zarnani, A.H., Soleimani, M., Nayernia, K., Ragerdi Kashani, I., 2017. Differentiation of bone marrow–derived stage–specific embryonic antigen 1 positive pluripotent stem cells into male germ cells. Microscopy research and technique 80, 430-440.

Tamadon, A., Mehrabani, D., Rahmanifar, F., Jahromi, A.R., Panahi, M., Zare, S., Khodabandeh, Z., Jahromi, I.R., Tanideh, N., Dianatpour, M., 2015. Induction of spermatogenesis by bone marrow–derived mesenchymal stem cells in busulfan–induced azoospermia in hamster. International journal of stem cells 8, 134.

Tharakan, T., Salonia, A., Corona, G., Dhillo, W., Minhas, S., Jayasena, C., 2020. The Role of Hormone Stimulation in Men With Nonobstructive Azoospermia Undergoing Surgical Sperm Retrieval. The Journal of Clinical Endocrinology & Metabolism 105, dgaa556.

Vij, S.C., Sabanegh Jr, E., Agarwal, A., 2018. Biological therapy for non-obstructive azoospermia. Expert Opin. Biol. Ther. 18, 19-23.
Xu, L., Liu, Y., Sun, Y., Wang, B., Xiong, Y., Lin, W., Wei, Q., Wang, H., He, W., Li, G., 2017. Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. Stem Cell. Res. Ther. 8, 1-11.

Yuan, Q.I., Zhang, Y.g., Chen, Q., 2020. Mesenchymal Stem Cell (MSC)-Derived Extracellular Vesicles: Potential Therapeutics as MSC Trophic Mediators in Regenerative Medicine. The Anatomical Record 303, 1735-1742.

Zhanbyrbekuly, U., Tamadon, A., Akhnazarov, S.K., Suleiman, M., Aynayev, E., Zhaparov, U., Zhankina, R., Ibragimov, A., Yessenuly, A., 2020. Using mesenchymal stem cells for the treatment of non-obstructive azoospermia. Urologiya (Moscow, Russia: 1999), 119-123.

Zhang, D., Liu, X., Peng, J., He, D., Lin, T., Zhu, J., Li, X., Zhang, Y., Wei, G., 2014. Potential spermatogenesis recovery with bone marrow mesenchymal stem cells in an azoospermic rat model. Int. J. Mol. Sci. 15, 13151-13165.